Forgetting to take antiseizure medications is associated with focal to bilateral tonic-clonic seizures, as revealed by a cross-sectional study

Suzuki, Hime; Mikuni, Nobuhiro; Ohnishi, Hirofumi; Yokoyama, Rintaro; Enatsu, Rei; Ochi, Satoko

doi:10.1371/journal.pone.0240082

Cited by 10 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over one-third of patients with epilepsy are non-adherent to the prescribed treatment regimen, and suboptimal adherence is an important cause of persisting seizures [ 47 ], as well as a risk factor for emergency department visits, hospital admissions, injuries, and even mortality [ 48 ], possibly due to SUDEP [ 49 ]. ASMs that need to be taken less frequently have been consistently associated with better adherence [ 50 ].…”

Section: Resultsmentioning

confidence: 99%

Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements

et al. 2021

View full text Add to dashboard Cite

Background When use of a single antiseizure medication (ASM) fails to induce seizure remission, add-on therapy is justified. Perampanel (PER) is approved in Europe as adjunctive therapy for focal, focal to bilateral tonic-clonic seizures and generalized tonic-clonic seizures. Aim of the study was to establish whether PER is suitable for first add-on use. Methods A Delphi methodology was adopted to assess consensus on a list of 39 statements produced by an Expert Board of 5 epileptologists. Using an iterative process, statements were finalized by a Delphi Panel of 84 Italian pediatric and adult neurologists. Each statement was rated anonymously to determine level of agreement on a 9-point Likert scale. Consensus was established as agreement by at least 80% of the panelists. The relevance of each statement was also assessed on a 3-point scale. Results Consensus was achieved for 37 statements. Characteristics of PER considered to justify its use as first add-on include evidence of a positive impact on quality of life based on long term retention data, efficacy, tolerability, and ease of use; no worsening of cognitive functions and sleep quality; a low potential for drug interactions; a unique mechanism of action. Potential unfavorable factors are the need for a relatively slow dose titration; the potential occurrence of behavioral adverse effects; lack of information on safety when used in pregnancy; limited access to plasma PER levels. Conclusion Perampanel has many features which justify its use as a first add-on. Choice of an ASM as first add-on should be tailored to individual characteristics.

show abstract

Section: Resultsmentioning

confidence: 99%

Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Adherence was recorded using the MMAS in 16 of the included studies (see also Table 1 ). In half of those studies, the MMAS-4 [ 8 , 18 , 27 , 37 , 39 , 48 , 50 , 51 ] was used, whereas the other half used the MMAS-8 [ 21 , 23 , 29 , 34 , 52 , 53 , 54 , 55 ]. MMAS evaluates forgetfulness and modification of medication due to an improvement in wellbeing, as well as therapy-associated factors in terms of side-effects.…”

Section: Resultsmentioning

confidence: 99%

“…Likewise, a higher number of medications was associated with nonadherence in seven studies. Although Buck et al [ 22 ] identified monotherapy as a predictor of nonadherence, the majority of the studies reviewed found that a higher number of medications per day was associated with nonadherence [ 30 , 36 , 48 , 51 , 54 , 57 ]. Other reasons for nonadherence were the overall complexity of drug therapy [ 19 , 27 , 54 , 55 ], longer treatment duration [ 23 , 38 , 50 ], higher serum AED concentration [ 47 ], and concurrent valproate medication [ 40 , 48 ].…”

Section: Resultsmentioning

confidence: 99%

Detecting Reasons for Nonadherence to Medication in Adults with Epilepsy: A Review of Self-Report Measures and Key Predictors

Mendorf

Prell

Schönenberg

2022

JCM

View full text Add to dashboard Cite

This review presents individual reasons for self-reported nonadherence in people with epilepsy (PWE). A literature search was performed on the PubMed/Medline and Scopus databases for studies published up to March 2022. Thirty-six studies were included using the following inclusion criteria: original studies on adults with epilepsy, use of subjective self-report adherence measurement methods, and publication in English. Data were extracted using a standardized data extraction table, including the year of publication, authors, cohort size, study design, adherence measurement method, and self-reported reasons for nonadherence. Self-reported reasons for nonadherence were grouped following the WHO model with the five dimensions of nonadherence. In addition, study characteristics and sociodemographic information are reported. Of the 36 included studies, 81% were observational. The average nonadherence rate was nearly 50%. Across all studies, patient-associated, therapy-associated, and circumstance-related factors were the most frequently reported dimensions of nonadherence. These factors include forgetfulness, presence of side-effects, and history of seizures. Regarding healthcare system factors, financial problems were the most reported reason for nonadherence. Stigmatization and quality of life were the most frequently cited factors influencing nonadherence in the disease- and circumstance-related dimensions. The results suggest that interventions for improving adherence should incorporate all dimensions of nonadherence.

show abstract

“…A number of considerations which emerged from the consensus statements are more specifically relevant to first add-on use. In particular, suboptimal adherence to the prescribed treatment regimen is a common occurrence in individuals with epilepsy [19] and an important cause of persisting seizures [20]. Therefore, it was appropriate for the Panel to recommend that in individuals with uncontrolled seizures, the possibility of inadequate adherence to the previously used monotherapy regimen should be excluded prior to adding another medication.…”

Section: Discussionmentioning

confidence: 99%

Selection of antiseizure medications for first add-on use: A consensus paper

Gambardella

Tinuper

Acone³

et al. 2021

Epilepsy & Behavior

View full text Add to dashboard Cite

Introduction: When monotherapy used alone or sequentially fails to achieve seizure control, a trial of combination therapy may be considered. Objective: To define optimal criteria to guide choice of an antiseizure medication (ASM) for use as first add-on. Methods: A standardized Delphi procedure was applied to produce a list of consensus statements. First, an Expert Board consisting of 5 epileptologists agreed on a set of 46 statements relevant to the objective. The statements were then finalized through an iterative process by a Delphi Panel of 84 Italian pediatric and adult neurologists with expertise in the management of epilepsy. Panel members provided anonymous ratings of their level of agreement with each statement on a 9-point Likert scale. Results: Consensus, defined as agreement by at least 80% of Panel members, was reached for 36 statements. Medication-related factors considered to be important for drug selection included efficacy, tolerability and safety, interaction potential, mechanism of action, and ease of use. The need to optimize adherence and to tailor drug selection to individual characteristics was emphasized. Conclusions: Choice of an ASM for first add-on requires consideration of many factors, many of which also apply to choose initial treatment. Factors more specifically relevant to add-on use include drug interaction potential and the preference for an ASM with a different mechanism of action.

show abstract

Forgetting to take antiseizure medications is associated with focal to bilateral tonic-clonic seizures, as revealed by a cross-sectional study

Cited by 10 publications

References 30 publications

Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements

Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements

Detecting Reasons for Nonadherence to Medication in Adults with Epilepsy: A Review of Self-Report Measures and Key Predictors

Selection of antiseizure medications for first add-on use: A consensus paper

Contact Info

Product

Resources

About